You are here: Industry Insights > Ebola

News List

Additional $12mn to fund further development of Marburg virus vaccine europeanpharmaceuticalreview
June 25, 2021
BARDA has awarded more funding to Public Health Vaccines to support the development of a virally vectored vaccine against Marburg virus infections.
Johnson & Johnson to donate 200,000 vaccine regimens to curb Ebola outbreak europeanpharmaceuticalreview
May 18, 2021
To prevent the spread of the Ebola virus in West Africa, Johnson & Johnson is donating vaccines for a WHO early access clinical programme.
Gavi to make 500,000 doses of Ebola vaccine available for outbreak response europeanpharmaceuticalreview
January 25, 2021
The global stockpile will provide developing countries responding to Ebola outbreaks with doses of the approved single-dose Ebola vaccine, rVSV∆G-ZEBOV-GP, live, free of charge.
FDA approves Ebanga (Ansuvimab-zykl) for the treatment of Ebola europeanpharmaceuticalreview
January 06, 2021
Ebanga was approved based on its ability to reduce 28-day mortality in patients with confirmed Ebolavirus infection.
Ridgeback Biotherapeutics’ Ebola treatment scores FDA approval pharmatimes
December 24, 2020
Ridgeback Biotherapeutics’ Ebanga has been approved by the US Food and Drug Administration (FDA) for the treatment of Ebola in adult and paediatric patients.
FDA approves Regeneron’s Inmazeb for Ebola infection treatment pharmaceutical-technology
October 16, 2020
The US Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals’ Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) to treat Ebola virus infection in adult and paediatric patients.
Ridgeback Announces Initiation of Expanded Access Protocol for Ebola Treatment americanpharmaceuticalreview
August 31, 2020
Ridgeback Biotherapeutics announced the implementation of an expanded access protocol to ensure rapid access to its Ebola treatment, ansuvimab, in the Democratic Republic of the Congo (DRC).
Bavarian Nordic to Manufacture Additional Ebola Vaccines for Janssen contractpharma
June 19, 2020
Deal valued at $13.9 million; manufacturing to begin this year.
EMA gives positive opinion to investigational Ebola vaccine regimen europeanpharmaceuticalreview
June 09, 2020
Developed by Janssen, the two-dose regimen has already been given to 60,000 patients and now has the positive opinion of the Committee for Medicinal Products for Human Use (CHMP).
New vaccine for Ebola among CHMP recommendations pharmatimes
June 02, 2020
Johnson and Johnson's experimental two-stage vaccine for protection against Ebola virus disease is among eight medicines backed by the European Medicines Agency's human medicines committee (CHMP) at its May meeting.

Previous page 1 2 3 4 5 6 7 Next page